[A23-70] Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15
Last updated 17.08.2023
Project no.: A23-70
Commission: Commission awarded on 11.07.2023 by the Federal Joint Committee (G-BA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Kidneys and urinary system
Indication:
Adults with chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes mellitus
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.